zacks.com
Should You Continue to Hold Integra Stock in Your Portfolio Now?
IART faces macro headwinds and tight liquidity, but strong demand in its Codman Specialty Surgical unit and expanding international launches could support growth.
Integra LifeSciences Holdings CorporationIARTNASDAQ
Loading
Latest News
zacks.com
Integra Q4 Earnings & Revenues Beat Estimates, Margins Down, Stock Up
IART tops Q4 EPS and revenue estimates despite margin pressure and a sales dip, as shares edge higher and 2026 guidance signals modest growth.
zacks.com
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
seekingalpha.com
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
zacks.com
Integra (IART) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zacks.com
Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.97 per share a year ago.
globenewswire.com
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025.
globenewswire.com
Integra LifeSciences Announces Key Executive Leadership Appointments
PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Teshtar Elavia as corporate vice president and chief technology officer, a newly created position to lead research and development (R&D), including product and technology development, across the company.
globenewswire.com
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026
PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
defenseworld.net
Brokerages Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Target Price at $15.00
Shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART - Get Free Report) have been given a consensus rating of "Reduce" by the seven brokerages that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy
defenseworld.net
Access Investment Management LLC Lowers Stake in Integra LifeSciences Holdings Corporation $IART
Access Investment Management LLC reduced its stake in Integra LifeSciences Holdings Corporation (NASDAQ: IART) by 14.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 372,450 shares of the life sciences company's stock after selling 63,420 shares during the period.
defenseworld.net
168,000 Shares in Integra LifeSciences Holdings Corporation $IART Purchased by Hussman Strategic Advisors Inc.
Hussman Strategic Advisors Inc. purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 168,000 shares of the life sciences company's stock, valued at approximately $2,407,000. Hussman Strategic Advisors Inc. owned
zacks.com
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
seekingalpha.com
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
defenseworld.net
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives $15.00 Average PT from Brokerages
Shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART - Get Free Report) have earned an average rating of "Reduce" from the seven research firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to
globenewswire.com
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m ET or 11:15 a.m PT
defenseworld.net
Integra LifeSciences Holdings Corporation $IART Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. lessened its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ: IART) by 62.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 454,352 shares of the life sciences company's stock after selling
seekingalpha.com
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
globenewswire.com
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under EVENTS & PRESENTATIONS.
globenewswire.com
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules.